3Finkelstein F, Healy H, Abu-Alfa A, et al. Superiority of icodextrin compared with 4.25% dextrose for peritoneal uhrafiltratio[ J]. J Am Soe Nephrol, 2005, 16(2) : 546 -554.
4Vonesh EF, Story KO, Douma CE, et al. Modeling of icodextrin in PD Adequest 2. O[ J]. Perit Dial Int, 2006, 26(4) : 475 - 481.
5Jeloka TK, Ersoy FF, Yavuz M, et al. What is the optimal dwell time for maximizing ultrafihration with icodextrin exchange in automated peritoneal dialysis patients[ J] ? Perit Dial Int, 2006, 26 (3) :336 -340.
6De Vriese AS, Tihon RG, Mortier S, et al. Myofibroblast transdifferentiation of mesothelial cells is mediated by RAGE and contributes to peritoneal fibrosis in uraemia [ J]. Nephrol Dial Transplant, 2006, 21 (9) : 2549 - 2555.
7Cooker LA, Holmes CJ, Hoff CM. Biocompatibility of icodextrin [ J]. Kidney Int Suppl, 2002, (81) : S34 -S45.
8Katsutani M, ho T, Masaki T, et al. Glucose-based PD solution, but not icodextrin-based PD solution, induces plasminogen activator inhibitor-1 and tissue-type plasminogen activator in human peritoneal mesothelial ceils via E RK1/2[ J]. Ther Apher Dial, 2007, 11 (2) :94 - 100.
9Ahmad M, Shah H, Pliakogiannis T, et al. Prevention of membrane damage in patient on peritoneal dialysis with new peritoneal dialysis solutions[ J]. Int Urol Nephrol, 2007, 39(1) : 299 - 312.
10Davies SJ, Woodrow G, Donovan K, et al. Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial[J]. J Am Soc Nephrol, 2003, 14(9): 2338 - 2344.
